ATE365043T1 - Endotoxinhemmern zur behandlung von kachexie - Google Patents

Endotoxinhemmern zur behandlung von kachexie

Info

Publication number
ATE365043T1
ATE365043T1 AT00916915T AT00916915T ATE365043T1 AT E365043 T1 ATE365043 T1 AT E365043T1 AT 00916915 T AT00916915 T AT 00916915T AT 00916915 T AT00916915 T AT 00916915T AT E365043 T1 ATE365043 T1 AT E365043T1
Authority
AT
Austria
Prior art keywords
lps
endotoxin
lipopolysaccharide
gut
patient
Prior art date
Application number
AT00916915T
Other languages
English (en)
Inventor
Hans-Dieter Volk
Mathias Plauth
Herbert Lochs
Original Assignee
Anker Stefan
Hans-Dieter Volk
Schumann Ralf Reiner
Coats Andrew
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9905314.2A external-priority patent/GB9905314D0/en
Priority claimed from GBGB9905307.6A external-priority patent/GB9905307D0/en
Priority claimed from GBGB9905315.9A external-priority patent/GB9905315D0/en
Priority claimed from GBGB9905300.1A external-priority patent/GB9905300D0/en
Priority claimed from GBGB9905310.0A external-priority patent/GB9905310D0/en
Application filed by Anker Stefan, Hans-Dieter Volk, Schumann Ralf Reiner, Coats Andrew filed Critical Anker Stefan
Application granted granted Critical
Publication of ATE365043T1 publication Critical patent/ATE365043T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00916915T 1999-03-09 2000-03-09 Endotoxinhemmern zur behandlung von kachexie ATE365043T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9905314.2A GB9905314D0 (en) 1999-03-09 1999-03-09 Therapy and use of compounds in therapy (2)
GBGB9905307.6A GB9905307D0 (en) 1999-03-09 1999-03-09 Therapy and use of compounds in therapy
GBGB9905315.9A GB9905315D0 (en) 1999-03-09 1999-03-09 Therapy and use of compounds in therapy
GBGB9905300.1A GB9905300D0 (en) 1999-03-09 1999-03-09 Therapy and use of agents in therapy
GBGB9905310.0A GB9905310D0 (en) 1999-03-09 1999-03-09 Therapy and use of compounds in therapy (4)

Publications (1)

Publication Number Publication Date
ATE365043T1 true ATE365043T1 (de) 2007-07-15

Family

ID=27517498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916915T ATE365043T1 (de) 1999-03-09 2000-03-09 Endotoxinhemmern zur behandlung von kachexie

Country Status (10)

Country Link
US (2) US20070197485A1 (de)
EP (2) EP1212064A2 (de)
AT (1) ATE365043T1 (de)
AU (2) AU4105600A (de)
CY (1) CY1107436T1 (de)
DE (1) DE60035262T2 (de)
DK (1) DK1158989T3 (de)
ES (1) ES2288847T3 (de)
PT (1) PT1158989E (de)
WO (2) WO2000053165A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302206A1 (de) * 2001-10-11 2003-04-16 Universitair Medisch Centrum Utrecht Verfahren und Mittel zur Verwendung des adventitial Toll-like-Rezeptors
US20040122067A1 (en) * 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
US7655237B2 (en) 2003-03-21 2010-02-02 Bridge Bioresearch Limited Use of soluble CD14 for treatment of type 2 diabetes mellitus
US7883701B2 (en) * 2003-12-19 2011-02-08 Wisconsin Alumni Research Foundation Method for enhancing growth or increasing feed efficiency through reducing binding between endotoxin and its receptor in the gastrointestinal tract
CN1964727A (zh) * 2004-06-02 2007-05-16 株式会社吴羽 循环器官功能障碍因子除去剂
TWI487535B (zh) 2004-11-30 2015-06-11 Centocor Inc 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
EP1741440A1 (de) * 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
WO2007051164A2 (en) 2005-10-27 2007-05-03 Centocor, Inc. Toll like receptor 3 modulators, methods and uses
KR100785656B1 (ko) * 2007-05-14 2007-12-17 재단법인서울대학교산학협력재단 소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체
EP2208497A1 (de) * 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Verwendung von Ursodesoxycholsäure (UDCA) zum Verbessern des allgemeinen Gesundheitszustands eines Tumorpatienten
CN115120681A (zh) * 2022-07-19 2022-09-30 浙江长三角聚农科技开发有限公司 竹笋生物炭在制备治疗糖尿病及其并发症药物中的应用
CN115137733B (zh) * 2022-08-24 2024-01-02 吉林大学 熊去氧胆酸在制备mcr-3酶抑制剂中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377595A (en) * 1979-08-13 1983-03-22 Massachusetts Institute Of Technology Process for reducing depression
US4898879A (en) * 1981-06-29 1990-02-06 Baxter International Inc. Nurtitional composition for management of hepatic failure
US5087453A (en) * 1990-11-01 1992-02-11 Otsuka Pharmaceutical Co., Ltd. Method for the treatment of bacterial caused weight loss and/or hypoglycemia
US5674855A (en) * 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
US5589358A (en) * 1993-12-29 1996-12-31 Univ Wake Forest Ileal bile acid transporter compositions and methods
IT1274000B (it) * 1994-04-06 1997-07-14 Alfa Wassermann Spa Derivati di acidi biliari utili nella terapia della calcolosi biliare da colesterolo e nelle patologie indotte da colestasi
US5763435A (en) * 1995-11-21 1998-06-09 Children's Hospital Medical Center Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue

Also Published As

Publication number Publication date
DE60035262T2 (de) 2008-02-21
ES2288847T3 (es) 2008-02-01
WO2000053165A2 (en) 2000-09-14
WO2000053165A3 (en) 2001-04-12
US20070197485A1 (en) 2007-08-23
AU4105600A (en) 2000-09-28
DK1158989T3 (da) 2007-10-22
DE60035262D1 (de) 2007-08-02
AU3809900A (en) 2000-09-28
PT1158989E (pt) 2007-10-01
US20090197851A1 (en) 2009-08-06
WO2000053224A3 (en) 2002-04-04
CY1107436T1 (el) 2012-12-19
WO2000053224A2 (en) 2000-09-14
EP1158989A2 (de) 2001-12-05
EP1158989B1 (de) 2007-06-20
EP1212064A2 (de) 2002-06-12

Similar Documents

Publication Publication Date Title
CY1107436T1 (el) Χρηση των αναστολεων της ενδοτοξινης για την θεραπεια της καχεξιας
Wersall et al. Ototoxicity of gentamicin
Stenvinkel Inflammatory and atherosclerotic interactions in the depleted uremic patient
CN102791262A (zh) 用于处理生物薄膜的d-氨基酸
ATE247974T1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
NO170114B (no) Elektrisk kontaktklemme
Scott et al. Adjuvant activity of saponin: antigen localization studies
ATE481111T1 (de) Pax2 zur behandlung von nierenkrankheiten
RU95112534A (ru) Дерматансульфаты и их соли, противотромбозные средства, способ предупреждения или лечения тромбозов, способ предупреждения или лечения синдрома рассеянной интраваскулярной коагуляции, способ лечения инфаркта миокарда
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
Trooskin et al. Failure of demonstrated clinical efficacy of antibiotic-bonded continuous ambulatory peritoneal dialysis (CAPD) catheters
Nagao et al. Immunotherapy for the treatment of acute paraquat poisoning
AU609909B2 (en) Urease antigen product & process
Jivegård et al. The effects of morphine and enkephaline on gallbladder function in experimental cholecystitis: Inhibition of inflammatory gallbladder secretion
US6753341B1 (en) Inhibition of PKC to treat permability failure
Neild et al. Severe systemic vascular necrosis in cyclosporin-treated rabbits with acute serum sickness.
Bennett et al. Effect of angiotensin-converting enzyme inhibitors on resistance artery structure and endothelium-dependent relaxation in two-kidney, one-clip Goldblatt hypertensive and sham-operated rats
CA2468496A1 (en) Ilk inhibitors for the treatment of renal disease
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
Strauss et al. Effect of Sulfated β-cyclodextrin, a Water Soluble Cycloamylose, on the Promotion and/or Inhibition of Angiogenesis
Nowotny et al. Studies on host defenses enhanced by endotoxins: a brief review
EP0790250A3 (de) Inhibitoren des biogenen Amin Transportes
El Munshid et al. Importance of the kidneys for gastrin elimination and gastric function

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1158989

Country of ref document: EP

REN Ceased due to non-payment of the annual fee